×

Uses of DPP IV inhibitors

DC CAFC
  • US 9,173,859 B2
  • Filed: 01/22/2014
  • Issued: 11/03/2015
  • Est. Priority Date: 05/04/2006
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating type 2 diabetes comprisingadministering to a patient in need thereof (a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a therapeutically active salt thereof, in an oral dosage of 2.5 mg or 5 mg, and (b) metforminwherein the dose of metformin is 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a day), or 300 mg to 1000 mg once or twice a day, or as delayed-release metformin in a dose of 500 mg to 1000 mg once or twice a day, or 500 mg to 2000 mg once a day, orwherein the dose of metformin is 500 mg, 850 mg or 1000 mg as a single dose with a total daily dose of metformin of 500-2850 mg, or 500 mg, 1000 mg, 1500 mg or 2000 mg metformin in delayed release form, orwherein the dose of metformin is 500 mg to 1000 mg.

View all claims
  • 0 Assignments
Timeline View
Assignment View
    ×
    ×